PHX 11.9% 4.7¢ pharmx technologies limited

Ann: Corum Clear Update, page-19

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 635 Posts.
    lightbulb Created with Sketch. 316
    I agree, although I'm not expecting a lot from the H2 result. If we exclude the interest earned on the cash balance, COO actually made a small EBITDA loss in H1. Accordingly, it would be a good result if the cost savings previously flagged drive a modestly positive H2 EBITDA. A marginal H2 EBITDA result will also mean that the H2 R&D spend will need to be funded from cash - hopefully the lions share of this R&D was spent in H1, although I suspect there will be some depletion of the (post tax refund) cash balance. Regardless, the main game is the approval and takeup of Corum Clear. This is what will drive positive earnings growth and underpin a rising share price. If successful, 6c+ should be readily achievable assuming it drives revenues back to the mid teens or more and EBITDA back to $2m+. This would also provide good flexibility to deploy the cash balance.
 
watchlist Created with Sketch. Add PHX (ASX) to my watchlist
(20min delay)
Last
4.7¢
Change
0.005(11.9%)
Mkt cap ! $28.12M
Open High Low Value Volume
4.2¢ 4.8¢ 4.2¢ $31.55K 693.9K

Buyers (Bids)

No. Vol. Price($)
1 74051 4.7¢
 

Sellers (Offers)

Price($) Vol. No.
4.9¢ 77252 1
View Market Depth
Last trade - 16.10pm 08/11/2024 (20 minute delay) ?
PHX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.